UBS’ Marc Goodman suspended coverage of Valeant Pharmaceuticals Intl Inc VRX, citing lack of transparency in the company’s financials and uncertainty over the timeline of the visibility.
Analyst Marc Goodman believes that under these circumstances it is not practical to forecast the company’s financial results and maintain an investment opinion.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in